Skip to content
OpenCapital
Get started

CorMedix CRMD Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value at other companies

Repligen logo
RepligenRGEN
$155.80—
AMN Healthcare logo
AMN HealthcareAMN
$80.79-9.9%
Kopin logo
KopinKOPN
$1.62—
Heartland Express logo
Heartland ExpressHTLD
$10.71-5.1%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$54.10+21.0%
Heartland Express logo
Heartland ExpressHTLD
$10.48-4.3%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×—
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%—
Net margin45.2%—
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%—
Debt / equity0×0.0×
Current ratio3×-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?
CorMedix (CRMD) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value of $10.5 in Q4 2025.
What is the long-term trend for CorMedix's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?
Over 2 years (2021 to 2025), CorMedix's share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value has grown at a 41.4% compound annual growth rate (CAGR), from $5.25 to $10.5.